Since the 1940s, doctors have been surgically removing the
thymus gland -- a procedure called thymectomy -- as a means of
treating myasthenia gravis. But this has been done based on
research indicating the gland
mightplay a role in the development of the disease.

"It has never been clearly shown to benefit patients beyond other medical therapies that have developed over time," said lead researcher Dr. Gil Wolfe. He's the chair of neurology for the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo in New York.

"There has always been a question of how much favorable impact it actually provides," Wolfe said.

Now, Wolfe and his colleagues have proven that thymectomy offers
real and lasting benefits for myasthenia gravis patients.

The researchers reported that patients treated with
thymectomy:

Were less affected by myasthenia gravis symptoms than patients
treated with prednisone alone, the main non-surgical treatment
option.

Required about one-third less prednisone and two-thirds less
other immune-suppressing medications during a three-year follow-up,
compared with patients who didn't receive the surgery.

Experienced a three-quarters reduction in hospitalizations due
to disease flare-up.

"This nails it down and finally demonstrates that there's a beneficial effect, it's pretty broad, and while it may not lead to complete resolution of symptoms, it does allow people to reduce the amount of medication they're on," said Dr. Allan Ropper. He's executive vice chair of neurology at Brigham and Women's Hospital and a professor at Harvard Medical School in Boston.

Myasthenia gravis occurs when the immune system attacks the
nerve receptors that control muscle contractions. As a result,
people suffer from debilitating muscle weakness, according to the
U.S. National Institutes of Health.

People with myasthenia gravis often experience weakness in the
muscles of the head and neck, which causes drooping eyelids,
blurred vision, difficulty swallowing and slurred speech, the
Myasthenia Gravis Foundation of America says.

But the disease also can affect life-sustaining body functions
such as breathing. Only a few decades ago, approximately one-third
of all patients with myasthenia gravis died from the disorder,
researchers said in background notes.

As many as 60,000 people in the United States have myasthenia
gravis. But the number may be higher due to underdiagnosis,
according to the Myasthenia Gravis Foundation of America.

The thymus gland is located in the chest. The gland plays a
major role in the early development of the immune system. The
gland's job is nearly done by adulthood, Ropper said, and in most
people it tends to shrink and be replaced by fat with age.

"Your body can do just fine without a thymus, especially if you're an adult," Ropper said.

In adults with myasthenia gravis, the thymus gland remains large
and becomes abnormal. Doctors have long suspected that the gland
somehow causes the condition by spurring the immune system into
attack mode.

Thymectomy has long been a treatment option. But, until this
study there had been no clinical trial to show whether the
procedure actually worked.

Prednisone, a steroid medication, is also a treatment option.
But the drug comes with severe side effects that may include fluid
retention, high blood sugar, an increase in blood pressure, bone
softening and cataracts, Ropper said.

According to Wolfe, "These findings solidly confirm the early
use of thymectomy in managing myasthenia gravis." In addition, the
study results "tell patients they can be even more assured that
thymectomy is a positive step to take in the management of their
condition."

The study ran from 2006 until 2012. It included 126 patients
with myasthenia gravis who participated at one of 36 centers on six
continents.

The patients were randomly placed into one of two treatment
groups. About half received a thymectomy and follow-up treatment
with prednisone. The rest of the study volunteers received
prednisone alone.

Wolfe praised the patients who agreed to participate in the
study. "You're asking patients to give up their decision on whether
to have a major procedure or not," he said. "We want to acknowledge
the patients who put their faith in us."

The study was funded by the U.S. National Institutes of Health,
the Muscular Dystrophy Association and the Myasthenia Gravis
Foundation of America.

Findings were published in the Aug. 11 issue of the
New England Journal of Medicine.

This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.

To send comments or feedback to our Editorial Team regarding the content please email us at healthlibrarysupport@ebsco.com. Our Health Library Support team will respond to your email request within 2 business days.